BIIB News and Press, Biogen Inc. From 05/01/24

2024-05-01 11:44:29 ET More on AbCellera Biologics AbCellera: Victim Of Its Own Success AbCellera Biologics Inc. (ABCL) Q4 2023 Earnings Call Transcript AbCellera Biologics: Continuing To Expand Partnerships Peter Thiel resigns from AbCellera board for person...

2024-04-30 13:40:00 ET Summary Biogen Inc. has faced challenges lately, including declining sales of its multiple sclerosis drugs and setbacks in developing an Alzheimer's drug. The company's stock price has fluctuated, reaching highs of over $350 per share but falling to lows of ...

2024-04-30 12:47:04 ET Summary Biogen Inc.'s Alzheimer therapy, Leqembi, is finally gaining traction with Q1 '24 sales of $19 million, nearly tripling Q4 revenues. The drug has faced challenges in gaining coverage and reimbursement, but it is expected to reach multi-billion dollar...

2024-04-29 09:00:00 ET Summary Biogen Inc.'s Q1 earnings missed estimates with a decrease in revenue; however, EPS showed minor improvements. Operational cost reductions contributed to the EPS gain despite revenue shortfall, with significant cuts in R&D spending. Skyclarys...

2024-04-27 10:00:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The Strategy underperf...

2024-04-25 10:30:05 ET Wedbush analyst issues NEUTRAL recommendation for BIIB on April 25, 2024 08:28AM ET. The previous analyst recommendation was Neutral. BIIB was trading at $204.65 at issue of the analyst recommendation. The overall analyst consensus : BUY. Curre...

2024-04-24 18:18:12 ET Before market open on Wednesday, Biogen (NASDAQ: BIIB) unveiled its first earnings report of 2024. Happily, the company was far more profitable than many expected it to be, and investors rewarded this performance by trading the stock up by almost 5%. That comp...

2024-04-24 17:04:29 ET Biogen, a global biopharmaceutical company, has seen revenue growth driven by higher returns in the U.S. Operating expenses have evolved, leading to improved net income in Q1 2024. Management focuses on internal initiatives and managing risks like market competition and...

2024-04-24 12:45:15 ET Image source: The Motley Fool. Biogen (NASDAQ: BIIB) Q1 2024 Earnings Call Apr 24, 2024 , 8:30 a.m. ET Operator Continue reading For further details see: Biogen (BIIB) Q1 2024 Earnings Call Transcript

2024-04-24 11:25:25 ET Biogen Inc. (BIIB) Q1 2024 Earnings Call Transcript April 24, 2024 05:00 PM ET Company Participants Chuck Triano - Head of Investor Relations Chris Viehbacher - President and Chief Executive Officer Alisha Alaimo - Head and President of Nor...